Nurix Therapeutics, Inc. Common stock (NRIX) Dividend History

Nurix Therapeutics, Inc. is a biotechnology company focused on developing innovative small molecule therapies that modulate the ubiquitin-proteasome system to treat cancer, autoimmune, and inflammatory diseases. The company's approach involves targeting protein degradation pathways to selectively manipulate cellular processes and restore healthy function. Founded to advance precision medicine, Nurix leverages its expertise in drug discovery to develop targeted therapeutics with potential for broad clinical applications.

1700 Owens Street, Suite 205, San Francisco, CA, 94158
Phone: (415) 660-5320
Website: http://www.nurixtx.com

Dividend History

Nurix Therapeutics, Inc. Common stock currently does not pay dividends

Company News

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics will host a webcast conference call to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress.

GlobeNewswire Inc.

Featured Companies: GILD PFE
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Sanofi agreed to acquire Blueprint Medicines for $9.5 billion, including the rare immunology disease medicine Ayvakit and a promising pipeline. The deal will expand Sanofi's rare and immunology portfolios.

Benzinga

Featured Companies: BPMC
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics presented data at the AACR 2025 Annual Meeting showcasing the potential of its DEL-AI platform to accelerate the discovery of novel drugs by using machine learning to predict binders for a wide range of therapeutic targets, including previously 'undruggable' ones.

GlobeNewswire Inc.

Featured Companies: GILD PFE
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics reported strong Q1 2025 results, including achieving milestones and a license extension fee from its collaboration with Sanofi, and advancing its pipeline of targeted protein degradation medicines, including the BTK degrader bexobrutideg.

GlobeNewswire Inc.
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted inducement awards to 13 new employees, including stock options and restricted stock units. The grants were made to support the company's growth and development of targeted protein degradation medicines.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 22:04:19 UTC